Introduction {#s1}
============

Non-coding RNAs are RNA molecules that are not translated into proteins. Recent advances in genomic sequencing technologies and functional assays enable a more in-depth understanding of their characteristics ([@B62]; [@B21]; [@B73]). The transcription process of non-coding RNAs is precisely orchestrated in time and space ([@B74]; [@B21]). Different developmental stages or tissue types have distinct transcriptional landscapes ([@B9]; [@B38]). The central nervous system is a sophisticated and precise system which is responsible for guiding our daily activities such as sports, learning, emotion and language. Rapidly growing evidence indicated that non-coding RNAs play indispensable roles in brain development, function, and the etiology of neurodevelopmental diseases.

Here, we review the diversity and biogenesis processes of non-coding RNAs, and summarize their versatile roles in neurodevelopmental disorders. We also discuss potential clinical applications of non-coding RNAs as diagnostic and prognostic markers and as therapeutic targets in neurodevelopmental disorders.

Characteristics of Non-Coding RNAs {#s2}
==================================

Abundant and functionally important types of non-coding RNAs include ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs), as well as regulatory non-coding RNAs which mainly consist of microRNA (miRNA), PIWI-interacting RNA (piRNA), small nucleolar RNA (snoRNA), small interfering RNAs (siRNAs), long non-coding RNA (lncRNA), and Circular RNAs (CircRNAs). Non-coding RNAs play a critical role in epigenetics regulation of gene expression in addition to their roles at the transcriptional and post-transcriptional level ([@B16]; [@B2]).

miRNAs are small single-stranded molecules (20--24 nt) that have seed sequences complementary to sequences on target mRNAs transcripts through the 3′UTR, leading to silencing of the target gene. The miRNA gene is transcribed by RNA polymerases II and III to generate a primary microRNA precursor molecule (pri-miRNA). The pri-miRNA then undergoes nuclear cleavage by Drosha/DGCR8 to form a precursor microRNA (pre-miRNA). The pre-miRNA is transported from the nucleus into the cytoplasm by Exportin 5, and then processed by Dicer/TRBP into a miRNA duplex which is unwound by a helicase. The mature miRNA is incorporated into the RNA-induced silencing complex (Risch et al.) which mediates down-regulation of gene expression by either translational repression or mRNA degradation ([@B16]; [@B24]; [@B79]) ([**Figure 1**](#f1){ref-type="fig"}).

![Common regulatory mechanism of non-coding RNAs **(A)** miRNAs modulate target genes by silencing mRNA translation or inhibiting mRNA transcription. **(B)** LncRNAs regulate gene transcription by three distinct ways. **(C)** PiRNAs target transposon for silencing its expression. **(D)** SnoRNAs inhibit transcription by targeting specific loci. **(E)** CircRNAs are able to repress miRNA expressions.](fgene-10-01033-g001){#f1}

piRNAs are small non-coding RNAs (24-31 nt) that can silence transposons and regulate gene expression by directing PIWI proteins of Argonaute family to specific genomic loci ([@B25]) ([**Figure 1**](#f1){ref-type="fig"}). piRNAs biogenesis is divided into primary and secondary pathways ([@B110]). In primary pathway, primary piRNAs are transcribed from genomic loci called piRNA clusters ([@B6]; [@B52]). Primary piRNAs are spliced by endonuclease into tail-to-head phased precursor piRNA that are catalyzed by the mitochondrial protein Zucchini/PLD6 ([@B34]; [@B71]; [@B25]). Each pre-piRNA begins with a 5′ monophosphate, a prerequisite for loading RNA into nearly all Argonaute proteins ([@B87]; [@B103]). Once the PIWI protein captures pre-piRNA, the 3′ terminal is trimmed by a single-stranded RNA exonuclease called Trimmer/PNLDC1 to the appropriate size ([@B40]; [@B92]; [@B19]). Finally, the small RNA methyltransferase Hen1/HENMT1 adds a 2-O-methyl moiety to the 3′ ends of the mature piRNAs ([@B32]; [@B54]). The secondary piRNA biogenesis pathway, also known as the "ping-pong" cycle, is a piRNA-directed piRNA synthesis pathway that produces a piRNA *via* interaction with PIWI proteins ([@B6]; [@B29]; [@B103]) ([**Figure 1**](#f1){ref-type="fig"}). So far, functions of piRNA are mainly concentrated in regulation of genomic stability *via* silencing transposon ([**Figure 1**](#f1){ref-type="fig"}).

snoRNAs are 60--300 nt nucleotide long, metabolically stable RNAs, which are usually concentrated in Cajal bodies or nucleoli ([@B20]). snoRNAs are produced by the transcription of RDR2. Compared with miRNA, snoRNA transcription events occur only in the nucleus ([@B99]). Initial, transcripts of snoRNA enter the cytoplasm for processing and modifying and subsequently return to the nucleus. snoRNA can catalyze sequence-specific 2′-O-methylation and pseudouridine acidification of ribosomal RNA (rRNA) by forming protein complexes with splicing function ([@B44]; [@B35]). A new study has found that snoRNAs are indispensable for processing and stability of lncRNA ([@B108]).

lncRNA are a family of long-chain non-coding RNA that are usually longer than 200 nt, which regulate various developmental and physiological processes ([@B33]; [@B112]; [@B51]). Almost all lncRNAs transcripts do not contain open reading frames ([@B106]), which are produced by RNA polymerase II, followed by capping and forming 3′polyadenylate tails ([**Figure 1**](#f1){ref-type="fig"}) ([@B51]). lncRNAs can interact with other epigenetic regulators to direct histone-modified enzymes or DNA-methylated enzymes to the specific gene loci and modulate gene expression ([@B96]; [@B28]). For example, BDNF-AS can recruit EZH2 and PRC2 complex to the promoter region of BDNF to down-regulate the expression of BDNF ([@B67]). In addition, lncRNAs might act as enhancers to activate gene transcription ([@B75]), and target miRNAs to silence their inhibitory functions ([@B10]; [@B47]). lncRNAs can also interact with proteins to modulate gene expression in different levels or direct their appropriate spatial subcellular localization ([@B14]; [@B51]).

Circular RNAs (CircRNAs) are recently emerged as a new class of endogenous noncoding RNAs (ncRNAs) which might regulate gene expression ([@B64]; [@B109]). These RNAs are usually processed into loops after transcription([@B78]). Large-scale sequencing and analysis results have demonstrated that thousands of circular RNAs are present in mammalian and nematodes ([@B64]; [@B53]). The published data also have indicated that CircRNAs are highly abundant in mammalian brain compared to other analyzed tissues ([@B64]). What's more, the majority of detected mouse CircRNAs are also expressed as CircRNAs in human brain, which suggests that CircRNAs are very conserved between species ([@B53]). Identically, transcription of circular RNA is orchestrated by developmental stage and tissue specificity([@B30]; [@B53]; [@B78]), which indicates that CircRNAs might serve as regulatory RNAs, especially in brain ([**Figure 1**](#f1){ref-type="fig"}). Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function ([@B30]; [@B78]). For example, cerebellar degeneration-related protein 1 transcript (CDR1as) contains more than 70 selectively conserved miRNA target sites. CDR1as strongly suppresses miR-7 activity and results in increased levels of miR-7 targets ([@B30]; [@B78]). Functionally, CDR1as and its interaction with miRNAs are important for sensorimotor gating and synaptic transmission ([@B78]). Using high resolution *in situ* hybridization technology, the researchers found that visualized CircRNAs punctate into the dendrites of neurons, and many CircRNAs change their abundance abruptly at a time corresponding to synaptogenesis. Together, these data indicate that CircRNAs play important roles in regulating synaptic function ([@B109]).

Non-Coding RNA in Neurodevelopmental Disorders {#s3}
==============================================

Human brain displays the richest repertoire of ncRNA species, and where several different ncRNA molecules are known to be involved in crucial steps for neurodevelopment ([@B63]; [@B89]; [@B73]). Abnormal expression of non-coding RNA has been linked with pathologies of several neurodevelopmental diseases, including Autism spectrum disorders (ASD), Fragile X syndrome (FXS), Down syndrome (DS), Rett syndrome, and Prader-Willi Angelman syndrome ([**Table 1**](#T1){ref-type="table"}).

###### 

Non-coding RNAs are related to neurodevelopmental disorders.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Neurodevelopmental Disorders   Dysregulated Non-coding RNAs                                                                                                                                                Functional examples                                                                                                                                                                                                                                                                                                                                                                              References
  ------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------
  Autism\                        miR-197-5p, miR-328-3p, miR-424-5p, miR-500a-5p, miR-313-5a. Up: miR-619-5p, miR-365a-3p miR-664a-3p, miR-188, RAY1/ST7, ST7OT1-4, ST7AS1-4, ST7OT1-3, SHANK2-AS, MSNP1AS   MiR-188 serves to fine-tune synaptic plasticity by regulating autism susceptibility genes Nrp-2 expression. Overexpression of SHANK2-AS reduces the complexity of neurites, and inhibits the proliferation of neuronal stem cells and promotes their apoptosis                                                                                                                                   ([@B90]; [@B93]; [@B50]; [@B41]; [@B95]; [@B98]; [@B68]; [@B18]; [@B15]; [@B43]; [@B59])
  Spectrum\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Fragile X\                     miR-302, miR-125, miR-132, let-7c, miR-9, miR-100, miR-124, miR-125a, miR-125b, miR-127, miR-128, miR-132, miR-138, miR-143, miR-219, FMR4, FMR5, FMR6                      MiR-125 and miR-132 interact with FMRP to regulate the signal transduction of metabolic glutamate receptors (mGluR1) and NMDAR. FMR4, FMR5 and FMR6 are detectable in the majority of patient leukocyte RNA samples.                                                                                                                                                                             ([@B46]; [@B42]; [@B89]; [@B24]; [@B98]; [@B56])
  Syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Down Syndrome                  miR-99a, let-7c, miR-125b-2, miR-155, miR-802                                                                                                                               DS dementia strongly correlates with overexpression of miR-155 on chromosome 21 with concomitant reduction of multiple CNS-functional targets, including BACH1, CoREST1, Cyclin D1, BCL6, BCL10, BIM, and SAPK4.                                                                                                                                                                                 ([@B61]; [@B26]; [@B3]; [@B94])

  Rett Syndrome                  miR-184, miR-30a, miR-381, miR-495, miR-130a, miR-132, miR-200a, miR-302c, DQ541777, AK081227, AK087060, BDNF-AS                                                            MiR-184, miR-30a, miR-381, and miR-495 are aberrantly up-regulated in MeCP2 knockout mice. These miRNAs are known for repressing the expression of important modulators of neuronal development, such as Bdnf and Numbl. BDNF is known to be aberrantly diminished in RTT individuals, it can be speculated that the lncRNA BDNF-AS might be an important therapeutic target for treating RTT.   ([@B72]; [@B97]; [@B107]; [@B77]; [@B55]; [@B66]; [@B39]; [@B83]; [@B111])

  Prader-Willi\                  SNRPN, SNRD116, Ube3a-ATS                                                                                                                                                   Mice with deletion of SNRD116 (MBII85) snoRNA clusters demonstrated obvious PWS phenotypes. In AS patients, the maternal Ube3a allele is inactive, the paternal allele is intact but epigenetically silenced through the Ube3a-ATS part of LNCAT at the Ube3a locus.                                                                                                                             ([@B69]; [@B48]; [@B88]; [@B85]; [@B17]; [@B8]; [@B65])
  syndrome\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  & Angelman\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Autism Spectrum Disorders {#s3_1}
-------------------------

ASD is a developmental disorder that affects communication and behavior, which is characterized by repetitive patterns of behavior, interests, or activities, problems in social interactions, and psychological problems in children ([@B5]). Children with ASD have co-occurring language problems, intellectual disabilities, and epilepsy at higher rates than the general population. While the exact cause of ASD has remained somewhat of a mystery, dozens of genes have been identified to potentially contribute to disease susceptibility ([@B23]; [@B4]; [@B82]; [@B45]; [@B37]). For example, polymorphisms in the FMR1 gene have been reported to be associated with autism ([@B80]), however, no consistent association between FMR1 polymorphisms and autism has been demonstrated. Therefore, ASD is probably not caused by one single genetic factor. Recent studies suggest that epigenetic mechanisms, such as non-coding RNAs, may play a major role in the pathogenesis of ASD ([@B15]).

Abnormal expression levels of miRNAs, including miR-132, miR-23a, miR-93, miR-106b, miR-146b and miRNA-148b, were observed in the serum, lymphoblastoid cells, or cerebellar cortex of autistic patients ([@B1]; [@B90]; [@B93]; [@B68]) ([**Figure 2**](#f2){ref-type="fig"}). Many autism susceptibility genes are predictive targets of these differently expressed miRNAs, which further strengthens the causal relationship between miRNAs and autism ([@B1]; [@B90]; [@B93]; [@B15]).

![Relationship between non-coding RNAs and neurodevelopmental disorders. **(A)** In Autism Spectrum Disorders, miR-132, miR-23a, miR-93, miR-106b, miR-146b and miRNA-148b, miR-197-5p, miR-328-3p, miR-424-5p, miR-619-5p, miR-500a-5p, miR-313-5a, miR-365a-3p and miR-664a-3p expression levels are abnormal. miR-188, RAY1/ST7 or ST7OT1-3, SHANK2-AS, MSNP1AS participate in ASD with distinct ways. **(B)** The interactions between non-coding RNAs and mechanism diagram of Fragile X Syndrome. microRNAs and long non-coding RNAs regulate Fragile X Syndrome process and might be a class of biomarkers of Fragile X Syndrome. **(C)** Dysregulation of microRNAs related to Down Syndrome in human fetal hippocampus and heart samples. **(D)** Left, the expression level of several microRNAs up-regulates in Rett Syndrome patients and these microRNAs play important roles in modulating neuronal development. Right, relationship between Mecp2 and Non-coding RNAs. **(E)** Microdeletion of SnoRNA SNRD (HBI-85) leads to Prader-Willi syndrome like phenotype. Long non-coding RNA Ube3a-ATS represses Ube3a, which gives rise to Angelman syndrome.](fgene-10-01033-g002){#f2}

A profiling study of circulating serum miRNAs in children with ASD reveals that differentially expressed miRNAs in serum may be involved in the molecular pathway of ASD ([@B43]), and serum miR-197-5p, miR-328-3p, miR-424-5p, miR-619-5p, miR-500a-5p, miR-313-5a, miR-365a-3p and miR-664a-3p may be served as potential biomarkers of ASD ([@B43]) ([**Table 1**](#T1){ref-type="table"}). Moreover, the interaction between miRNAs and autism risk genes in the cerebellum was observed in animal models of ASD. For example, miR-188 is down-regulated in autism patient ([@B95]) and is up-regulated in response to long-term potentiation ([@B50]). MiR-188 promotes dendritic spine formation by blocking the expression of neuropilin-2, a well-known candidate gene of ASD ([@B50]) ([**Figure 2**](#f2){ref-type="fig"}).

More than 200 lncRNAs are differentially expressed in the prefrontal cortex and cerebellum of ASD patients ([@B81]). The autism loci containing RAY1/ST7 (suppression of tumorigenicity 7) encode at least four non-coding genes (ST7OT1-4, ST7AS1-4) which are located in the sense or antisense chains that potentially regulate RAY1/ST7. Several rare mutations of RAY1/ST7 or ST7OT1-3 genes have been detected in autistic patients ([@B101]; [@B98]) ([**Figure 2**](#f2){ref-type="fig"}).

Genome-wide differential expression analysis of blood samples from ASD patients (Carninci et al.) identified 2407 up-regulated and 1522 down-regulated lncRNAs in peripheral blood leukocytes of ASD. The pathway enrichment analysis of these differently expressed lncRNAs revealed that they were mainly involved in synaptic vesicle circulation, long-term inhibition and long-term potentiation of neural pathways ([@B98]). Differential expression of lncRNAs *SHANK2-AS* and *BDNF-AS* was also observed in ASD ([@B98]; [@B104]; [@B91]) ([**Figure 2**](#f2){ref-type="fig"}). In neurons, *SHANK2-AS* and *Shank2* can form double-stranded RNA that inhibit the expression of *Shank2*. Overexpression of *SHANK2-AS* reduces the complexity of neurites, and inhibits the proliferation of neuronal stem cells and promotes their apoptosis ([@B59]).

Moesin is a protein that in human is encoded by the MSN gene, which regulates neuronal structure and immune response. MSN-binding *MSNP1-AS* is highly expressed in postmortem cerebral cortex samples from individuals with ASD. Increased *MSNP1-AS* expression is also observed in individuals carrying the ASD-associated rs4307059 T allele ([@B41]) ([**Figure 2**](#f2){ref-type="fig"}). By targeting the *MSNP1-AS* gene promoter, *MSNP1-AS* knockdown disrupts the expression of 318 genes in neuroblastoma neural progenitor cells, many of which are involved in chromatin organization and immune response, indicating multiple transcriptional and translational functions of *MSNP1AS* in ASD-relevant biological processes ([@B18]) ([**Table 1**](#T1){ref-type="table"}).

Fragile X Syndrome {#s3_2}
------------------

FXS is the most common inherited cause of mental disorder and ASD ([@B56]; [@B31]). FXS is caused by FMR1 (fragile X mental retardation 1) inactivation or dysfunction ([@B100]). FMR1 is required for normal neuronal connectivity and plasticity. The *FMR1* gene contains a CGG-repeat present in the 5′UTR which can be unstable upon transmission to the next generation. FXS patients have a repeat length exceeding 200 CGGs that generally leads to methylation of the repeat and the promoter region, resulting in silencing of *FMR1* gene expression ([@B27]; [@B22]; [@B91]).

Several miRNAs have already been proven to involve in the development of FXS ([@B56]). During the embryonic stage, miR-302 is specifically expressed by embryonic stem cells, and it blocks the translation of FMR1, which is required to repress differentiation. At blastocyst stage, down-regulation of miR-302 promotes FMRP synthesis and subsequent neuronal development. In the normal neuronal development, FMRP, as an RNA-binding protein, interacts with miR-125 and miR-132 to regulate the signal transduction of metabolic glutamate receptors (mGluR1) and N-methyl-D-aspartate receptors (NMDAR) ([@B56]) ([**Figure 2**](#f2){ref-type="fig"}). In addition, let-7c, miR-9, miR-100, miR-124, miR-125a, miR-125b, miR-127, miR-128, miR-132, miR-138, miR-143 and miR-219 might also interact with fragile X mental retardation protein (FMRP) to regulate neuronal development ([@B56]) ([**Table 1**](#T1){ref-type="table"}).

LncRNAs have recently emerged to influence the pathogenesis of FXS ([@B24]; [@B89]; [@B98]). The FMR1 bidirectional promoter is capable of translating lncRNA *FMR4* or *FMR1-AS1* which is an antisense transcription that overlaps the CGG repeat region ([@B42]; [@B46]) ([**Figure 2**](#f2){ref-type="fig"}). *FMR4* plays a critical role in regulating cell cycle, proliferation, and apoptosis of human neural precursor cells ([@B42]).

LncRNAs FMR5 and FMR6 have recently been linked to FXS ([@B76]) ([**Figure 2**](#f2){ref-type="fig"}). FMR5 is a sense lncRNA transcribed upstream of the FMR1 promoter, while FMR6 is an antisense transcript overlapping the 3′-UTR of FMR1. The expression of FMR4, FMR5, and FMR6 is detectable in the majority of patient leukocyte RNA samples, suggesting that it may be reliable biomarkers for FXS ([@B102]).

Down Syndrome {#s3_3}
-------------

DS is a neurodevelopmental disorder caused by the presence of all or part of a third copy of chromosome 21 ([@B3]). This disorder has been characterized with many clinical manifestations, including dementia, defects of the immunity system and congenital heart, and abnormalities of facial growth, gastrointestinal tract, and endocrine system ([@B61]). Five miRNAs (miR-99a, let-7c, miR-125b-2, miR-155 and miR-802) have been found to be overexpressed in human fetal hippocampus and heart samples from individuals with DS ([@B26]) ([**Figure 2**](#f2){ref-type="fig"}). Let-7c and miR-125b have been shown to enhance neuronal aging and degeneration ([@B12]). Recent evidence suggests that DS dementia strongly correlates with overexpression of miR-155 on chromosome 21 with concomitant reduction of multiple CNS-functional targets, including BACH1, CoREST1, Cyclin D1, BCL6, BCL10, BIM, and SAPK4 ([@B94]) ([**Figure 2**](#f2){ref-type="fig"}).

Rett Syndrome {#s3_4}
-------------

RTT is a neurodevelopmental disorder caused by the loss of function of methyl-CpG-binding protein 2 (MeCP2) ([@B11]; [@B73]). Because chromosome Y does not exist MeCP2, the disease occurs almost entirely in women ([@B105]; [@B73]). MeCP2 protein is highly expressed in neurons, acting as a transcriptional repressor and activator, depending on the context ([@B58]). Growing evidence suggests that various non-coding RNAs might play important roles in the development of RTT ([@B73]).

Due to direct or indirect deregulation following MeCP2 loss of function, disrupted miRNA expression has been reported in the disease progress of RTT ([@B97]; [@B60]). For instance, miR-184, miR-30a, miR-381, and miR-495 are aberrantly up-regulated in MeCP2 knockout mice ([@B72]; [@B107]) ([**Figure 2**](#f2){ref-type="fig"}). These miRNAs are known for repressing the expression of important modulators of neuronal development, such as *Bdnf* and *Numbl* ([@B57]; [@B107]). MeCP2 also interacts with pri-miRNA processing machines and affects their activity. For example, DGCR8/Drosha complex can be inhibited by MeCP2, thus affecting nuclear miRNA processing and dendritic growth ([@B13]). Interestingly, miRNAs can also regulate MeCP2 transcription, such as miR-130a ([@B111]), miR-132 ([@B60]), miR-200a, and miR-302c ([@B83]) ([**Figure 2**](#f2){ref-type="fig"}). Future studies on the link between MeCP2 and the miRNA population will broaden our knowledge of regulatory network affected in RTT and will help develop better therapeutic strategies.

PiRNA expression levels are altered globally in the absence of MeCP2 ([@B86]). There are at least 12 hippocampus-abundant piRNAs up-regulated with a fold change of over 1.5 in the cerebellum of MeCP2 KO mice. Among them, DQ541777, which is implicated in regulating the size of dendritic spines, is the 5th most abundant piRNA in the cerebellum libraries ([@B49]; [@B86]) [**Figure 2**](#f2){ref-type="fig"}. More specific functions of these dysregulated piRNAs in the pathophysiology of RTT are expected to be discovered in near future.

The aberrant lncRNA transcriptome is also present in the brain of RTT mice. For instance, the AK081227 and AK087060 transcripts are up-regulated in MeCP2-null brains ([@B77]). The overexpression of AK081227 mediated by the Mecp2 loss is associated with the down-regulation of its host coding protein gene *Gabrr2*, a major inhibitory neurotransmitter in the mammalian brain where it acts at GABA receptors, which are ligand-gated chloride channels ([@B77]). The neurotrophic BDNF is known to be aberrantly diminished in RTT individuals ([@B39]), it can be speculated that the lncRNA BDNF-AS might be an important therapeutic target for treating RTT. Although lncRNAs play an important role in neuronal development, their roles in the pathogenesis of RTT is largely unknown ([@B66]; [@B55]; [@B70]).

Prader-Willi Syndrome and Angelman Syndrome {#s3_5}
-------------------------------------------

Chromosome 15q11-q13 is a region containing a lot of genomic imprinting genes ([@B36]). Prader-Willi Syndrome (PWS) and Angelman Syndrome (AS) are two different types of neurodevelopmental disorders which are caused by loss of function or overexpression of at least one imprinted gene at the 15q11-q13 locus ([@B36]). PWS is characterized by intellectual disability, irritability, short stature, and low fertility/hypogonadism ([@B8]). NECDIN and small ribonucleoprotein polypeptide N (SNRPN) are functionally related to the pathological features of the disease (Francoise Musctelli, 2000). SNRPN downstream introns contain SNRD116 (HBII-85) snoRNA clusters, and paternal genetic microdeletion of SNRPN clusters might lead to PWS ([@B85]; [@B17]) ([**Figure 2**](#f2){ref-type="fig"}). Actually, mice with deletion of MBII85 snoRNA clusters demonstrated obvious PWS phenotypes ([@B88]), indicating non-coding RNAs can be tightly regulated and may play critical roles in the pathology of PWS.

The pathological features of AS include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance ([@B8]). AS is caused by the deletion and/or mutation of *Ube3a* on the maternal chromosome. While in patients with AS the maternal *Ube3a* allele is inactive, the paternal allele is intact but epigenetically silenced through the *Ube3a-ATS* part of LNCAT (large non-coding antisense transcript) at the Ube3a locus ([@B84]). Elucidating the mechanisms of how Ube3a-ATS involves in silencing the paternal *Ube3a* may lead to new therapies for AS ([@B48]; [@B65]) ([**Figure 2**](#f2){ref-type="fig"}).

Conclusions {#s3_6}
-----------

Non-coding RNAs have emerged as important regulators in the brain development and function. Although the number and functional subclasses of non-coding RNAs has steadily increased, it still likely represents only a small fraction of the total RNA transcriptome underlying the ontogeny and functional complexity of mammalian brain functions in health and disease. Aberrant expression of non-coding RNAs has linked with various neurodevelopmental diseases. The regulatory network of non-coding RNAs in neurodevelopmental disorders is very complicated, and the molecular mechanisms of non-coding RNA causing neurodevelopmental diseases are still largely unknown. However, we still hope that this review raises awareness of the central roles that large non-coding RNAs and their complex regulatory networks in brain development and function.

With more defined molecular function and mechanism, Non-coding RNAs have the great potential to serve as disease biomarkers or drug targets, especially in neurodevelopmental disorders. For example, miR-132, miR-23a, miR-93, miR-106b, miR-146b and miRNA-148b are abnormally expressed in autistic patients (Mahesh Mundalil Vasu1, 2014; [@B95]). miR-99a, let-7c, miR-125b-2, miR-155 and miR-802 are found to be overexpressed in human samples from individuals with Down Syndrome([@B26]). In fragile X syndrome, the expression of FMR4, FMR5, and FMR6 is detectable in the majority of patient leukocyte RNA samples, suggesting that it may be reliable biomarkers for Fragile X Syndrome ([@B102]). The analysis and integration of this information with other datasets will get new clues of non-coding RNAs as reliable biomarkers.

A large number of studies have suggested that non-coding RNAs might be new promising targets for the treatment of neurodevelopmental disorders. However, several challenges remain to be investigated before non-coding RNAs can be routinely used in outbreak investigation and clinical practice. Firstly, more efficient non-coding RNAs delivery systems are needed to develop. Secondly, the biology of non-coding RNAs, such as their structural motifs, stability, degradation, and gene regulatory network, needs further investigations. Finally, preclinical research and clinical trials are required to determine the safe dose and therapeutic potentials of non-coding RNAs.

In addition, how non-coding RNAs operate in CNS at the molecular, cellular and more hierarchical neural network levels still remains elusive. Therefore, it is important to discover molecules based on further elucidating more pathways of non-coding RNA roles in the CNS and how non-coding RNA dysfunction leading to neurodevelopmental disorders. Based on more understanding of non-coding RNAs in the CNS, the researchers will probably develop new diagnostic and therapeutic approaches for neurodevelopmental disorders.
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